Rocket Pharmaceuticals, Inc.
RCKT
$3.39
-$0.15-4.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.25% | 41.25% | 45.00% | 40.71% | 35.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.98% | 3.20% | 6.45% | 3.45% | 4.70% |
| Operating Income | 0.98% | -3.20% | -6.45% | -3.45% | -4.70% |
| Income Before Tax | -1.60% | -3.49% | -5.35% | -2.15% | -1.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.60% | -3.49% | -5.35% | -2.15% | -1.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.60% | -3.49% | -5.35% | -2.15% | -1.91% |
| EBIT | 0.98% | -3.20% | -6.45% | -3.45% | -4.70% |
| EBITDA | 1.78% | -2.34% | -5.72% | -2.75% | -4.22% |
| EPS Basic | 10.36% | 8.40% | 7.00% | 14.34% | 16.29% |
| Normalized Basic EPS | 11.56% | 8.72% | 7.06% | 13.65% | 14.61% |
| EPS Diluted | 10.36% | 8.40% | 7.00% | 14.34% | 16.29% |
| Normalized Diluted EPS | 11.56% | 8.72% | 7.06% | 13.65% | 14.61% |
| Average Basic Shares Outstanding | 13.64% | 13.01% | 12.83% | 18.81% | 21.48% |
| Average Diluted Shares Outstanding | 13.64% | 13.01% | 12.83% | 18.81% | 21.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |